FMO6P

Across TCGA pan-cancer cohorts, FMO6P RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated FMO6P data layer compared with 1 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FMO6P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FMO6P expression acts as an unfavorable survival marker, although some lineages such as LUSC and SKCM show a favorable association.

BLCA, LUSC, and SKCM are the cancer types where FMO6P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.234	0.589	<.001	58	view →
LUSC	DFS	Median	All	0.477	0.332	.001	46	view →
SKCM	OS	Tertile	All	0.914	0.859	.005	40	view →
COAD	OS	Tertile	IV	0.318	0.731	.001	31	view →
READ	DFS	Tertile	IV	0.476	0.683	.012	30	view →
UCEC	OS	Median	All	0.779	0.592	<.001	26	view →
KIRC	OS	Median	II,III,IV	0.635	0.459	.008	20	view →
UCS	OS	Quartile	III,IV	0.349	0.711	.029	18	view →
LUAD	DFS	Tertile	IV	0.292	0.843	.002	18	view →
CESC	OS	Quartile	All	0.926	0.815	.024	14	view →
LIHC	DFS	Median	III,IV	0.387	0.103	.005	14	view →
PAAD	OS	Median	II,III,IV	0.688	0.452	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

FMO6P–BLCA (DFS)

Open the BLCA breakdown →